May 1968

The "Glucose Effect" in Erythropoietic Protoporphyria

Author Affiliations

Los Angeles

From the Department of Medicine, School of Medicine, University of Southern California and the John Wesley County Hospital, Los Angeles. Doctor Redeker is a recipient of a Public Health Service research career development award from the National Institutes of Health.

Arch Intern Med. 1968;121(5):446-448. doi:10.1001/archinte.1968.03640050056011

Erythropoietic protoporphyria (EPP) is an inherited photocutaneous disorder first described in 1961.1 The typical syndrome includes cutaneous photosensitivity, greatly increased erythrocyte and fecal protoporphyrin, and a variable but often marked increase in plasma protoporphyrin. The urine is normal.

Although the photosensitivity is clearly due to protoporphyrin, the site of formation of this porphyrin has been questioned. Initially it was suggested that the photosensitivity was associated with the high red cell porphyrin. However, in keeping with the other cutaneous porphyrias, increased porphyrin in the plasma was subsequently demonstrated.2,3 The possibility that the plasma porphyrin causes the photosensitivity and is synthesized at a nonerythropoietic site was suggested by Redeker and Bryan in 1964.4

The rate-limiting enzyme for porphyrin biosynthesis is aminolevulinic acid synthetase (ALA-S). Hepatic ALA-S is an inducible enzyme in patients with acute intermittent porphyria (AIP) and its rate of synthesis is reciprocal with carbohydrate or protein intake

First Page Preview View Large
First page PDF preview
First page PDF preview